Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MasterCard Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.3 (market cap $4.89B), while MasterCard Inc trades at $568.1 (market cap $496.73B). The key difference: MasterCard Inc is far larger — about 101.6× ACADIA Pharmaceuticals Inc.'s market cap, and MasterCard Inc pays a 0.61% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MA | |
|---|---|---|
Market Cap | $4.89B | $496.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.45 | $598.96 |
52-Week Low | $20.06 | $471.55 |
Enterprise Value | $4.01B | $509.77B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
Mastercard (MA) trades at $568.32, up 1.53% today, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $5.11. Revenue and net income have grown steadily, reaching $32.79B and $14.97B in 2025, respectively. Analyst consensus is strongly bullish with a $660.85 price target. Recent news highlights institutional buying and strategic initiatives in AI and digital payments.
The outlook for MA remains positive, driven by robust earnings growth, high profitability margins, and strategic expansion into digital and AI-driven payments. Key risks include competitive pressures from emerging payment technologies and regulatory challenges. With no sell ratings and significant institutional support, the stock presents a compelling opportunity for growth-oriented investors, though market volatility and economic shifts warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
